Evidence map›Paper›PMID 31077527›Full record

ArticleHepatology research : the official journal of the Japan Society of Hepatology2019

Real-world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group.

Toshie Mashiba, Kouji Joko, Masayuki Kurosaki, Hironori Ochi, Chitomi Hasebe, Takehiro Akahane, Tetsuro Sohda, Keiji Tsuji, Akeri Mitsuda, Hiroyuki Kimura and 18 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatology research : the official journal of the Japan Society of Hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 20 institutions in 2 countries.

Toshie MashibaCenter for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Ehime, Japan.
Kouji JokoCenter for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Ehime, Japan.
Masayuki KurosakiDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
Hironori OchiCenter for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Ehime, Japan.
Chitomi HasebeDepartment of Gastroenterology, Japanese Red Cross Asahikawa Hospital, Hokkaido, Japan.
Takehiro AkahaneDepartment of Gastroenterology, Ishinomaki Red Cross Hospital, Miyagi, Japan.
Tetsuro SohdaHepatology Division, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan.
Keiji TsujiDepartment of Gastroenterology, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan.
Akeri MitsudaDepartment of Internal Medicine, Japanese Red Cross Tottori Hospital, Tottori, Japan.
Hiroyuki KimuraDepartment of Gastroenterology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
Ryoichi NaritaDepartment of Gastroenterology, Oita Red Cross Hospital, Oita, Japan.
Chikara OgawaDepartment of Gastroenterology, Takamatsu Red Cross Hospital, Kagawa, Japan.
Koichiro FurutaDepartment of Internal Medicine, Masuda Red Cross Hospital, Shimane, Japan.
Masaya ShigenoDepartment of Gastroenterology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan.
Hiroaki OkushinDepartment of Gastroenterology, Japanese Red Cross Society Himeji Hospital, Hyogo, Japan.
Hiroshi ItoDepartment of Gastroenterology, Fukaya Red Cross Hospital, Saitama, Japan.
Atsunori KusakabeDepartment of Gastroenterology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Aichi, Japan.
Takashi SatouDepartment of Gastroenterology, Nasu Red Cross Hospital, Tochigi, Japan.
Chiharu KawanamiDepartment of Gastroenterology, Otsu Red Cross Hospital, Shiga, Japan.
Ryo NakataDepartment of Gastroenterology, Japanese Red Cross Medical Center, Tokyo, Japan.
Haruhiko KobashiDepartment of Gastroenterology, Japanese Red Cross Okayama Hospital, Okayama, Japan.
Takashi TamadaDepartment of Gastroenterology, Takatsuki Red Cross Hospital, Takatsuki, Japan.
Yasushi IdeDepartment of Internal Medicine, Karatsu Red Cross Hospital, Saga, Japan.
Hitoshi YagisawaDepartment of Gastroenterology, Japanese Red Cross Akita Hospital, Akita, Japan.
Atsuhiro MoritaDepartment of Gastroenterology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
Tomomichi MatsushitaDepartment of Gastroenterology, Japanese Red Cross Gifu Hospital, Gifu, Japan.
Kazuhiko OkadaDepartment of Gastroenterology, Toyama Red Cross Hospital, Toyama, Japan.
Namiki IzumiDepartment of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
Matsuyama Red Cross Hospital · JPMusashino Red Cross Hospital · JPTakamatsu Red Cross Hospital · JPAkita Red Cross Hospital · JPGifu Red Cross Hospital · JPHimeji Red Cross Hospital · JPHiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital · JPJapanese Red Cross Asahikawa Hospital · JPJapanese Red Cross Fukuoka Hospital · JPJapanese Red Cross Medical Center · JPJapanese Red Cross Nagoya Daini Hospital · JPJapanese Red Cross Society, Japan · JPJapanese Red Cross Society Kyoto Daini Hospital · JPKyoto first Red Cross hospital · JPOita Red Cross Hospital · JPOkayama Red Cross General Hospital · JPOtsu Red Cross Hospital · JPRed Cross Hospital · GRSaitama Red Cross Hospital · JPTakatsuki Red Cross Hospital · JP

Funding

Japan Agency for Medical Research and Development (AMED)
6 · The paper itself

Abstract

aimThe present study aimed to determine the real-world efficacy and safety of the non-structural protein (NS)5A inhibitor elbasvir (EBR) combined with the NS3/4A protease inhibitor grazoprevir (GZR) in patients with hepatitis C virus (HCV) genotype 1 (GT1) infection.

methodsThis study retrospectively evaluated the rate of sustained virologic response at 12 weeks post-treatment (SVR12) and the safety of EBR/GZR treatment in 159 men and 194 women with a median age of 72 years, and it assessed factors associated with the SVR12 rate. The attending physicians were responsible for selecting candidate patients for EBR/GZR in this retrospective study.

resultsTreatment outcomes for EBR/GZR were good in direct-acting antiviral (DAA)-naïve patients, of whom 99.4% achieved SVR. Of 353 patients, 10 (2.9%) had treatment failure. Of these patients, eight previously underwent DAA therapy, and the remaining two had NS5A-L31/Y93 double mutation. The SVR rate was 50% (8/16 patients) in patients who previously underwent DAA therapy, and 18.2% (2/11 patients) in patients with NS5A-L31/Y93 double mutation. On multivariate logistic regression analysis, NS5A-Y31/Y93 double mutation (odds ratio 356.3; 95% confidence interval, 23.91-16 940; P < 0.0001) was identified as an independent predictor of treatment failure. No serious adverse events were observed with EBR/GZR therapy.

conclusionsThe SVR rate of EBR/GZR would have been 100% in patients without either a history of DAA therapy or double mutation. This combination of drugs could be safely given and is, thus, considered a highly useful first-line treatment for DAA-naïve patients with HCV.

Indexed as

elbasvirgenotype 1grazoprevirhepatitis C virusresistance-associated substitution

Identifiers

PMID31077527
PMCPMC6899599
OpenAlexW2944304779

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.